Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H30O4 |
| Molecular Weight | 430.5354 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C5=CC=C6OCOC6=C5
InChI
InChIKey=DFELGYQKEOCHOA-BZAFBGKRSA-N
InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1
| Molecular Formula | C28H30O4 |
| Molecular Weight | 430.5354 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
ORG-34517 (or PT 150), a glucocorticoid receptor antagonist was development by Organon for the treatment of depression. This drug has completed phase II clinical trial for patients with major depression with psychotic features, however, this study was discontinued. In addition, Pop Test Cortisol LLC is developing ORG-34517 for the treatment of alcoholism. Now, this drug is in phase I clinical trial on stage recruiting to evaluate its safety when it is taken concurrently with alcohol.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| CRF1 but not glucocorticoid receptor antagonists reduce separation-induced distress vocalizations in guinea pig pups and CRF overexpressing mouse pups. A combination study with paroxetine. | 2017-03 |
|
| Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis activation. | 2015-09-01 |
|
| Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line. | 2008-12 |
Patents
Sample Use Guides
Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times. Intervention 1 includes PT150 (ORG-34517) with alcohol consumption
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:27:18 GMT 2025
by
admin
on
Mon Mar 31 18:27:18 GMT 2025
|
| Record UNII |
17VAN37K4Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000178427
Created by
admin on Mon Mar 31 18:27:18 GMT 2025 , Edited by admin on Mon Mar 31 18:27:18 GMT 2025
|
PRIMARY | |||
|
9867361
Created by
admin on Mon Mar 31 18:27:18 GMT 2025 , Edited by admin on Mon Mar 31 18:27:18 GMT 2025
|
PRIMARY | |||
|
189035-07-2
Created by
admin on Mon Mar 31 18:27:18 GMT 2025 , Edited by admin on Mon Mar 31 18:27:18 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545391
Created by
admin on Mon Mar 31 18:27:18 GMT 2025 , Edited by admin on Mon Mar 31 18:27:18 GMT 2025
|
PRIMARY | |||
|
17VAN37K4Y
Created by
admin on Mon Mar 31 18:27:18 GMT 2025 , Edited by admin on Mon Mar 31 18:27:18 GMT 2025
|
PRIMARY | |||
|
SUB194126
Created by
admin on Mon Mar 31 18:27:18 GMT 2025 , Edited by admin on Mon Mar 31 18:27:18 GMT 2025
|
PRIMARY | |||
|
DB05423
Created by
admin on Mon Mar 31 18:27:18 GMT 2025 , Edited by admin on Mon Mar 31 18:27:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
